California Institute for Regenerative Medicine
Encapsulated pancreatic cells differentiated from human embryonic stem cells
Encapsulated Pro-Islet™ graft containing pancreatic endocrine cells. In these images, blue represents insulin, red is glucagon, and green is somatostatin.
Pancreatic progenitor cells made from human embryonic stem cells in vitro are loaded into encapsulation device before transplantation. Cells mature into the different pancreatic endocrine cells, including importantly, insulin-expressing beta cells. These cells produce insulin in response to glucose, effectively replacing the insulin that is lost in people with type 1 diabetes. ViaCyte has several CIRM grants to develop a stem cell-based therapy for type 1 diabetes based on this work.
Image taken by Kuniko Kadoya, PhD at Viacyte, Inc.
Encapsulated pancreatic cells differentiated from human embryonic stem cells
Encapsulated Pro-Islet™ graft containing pancreatic endocrine cells. In these images, blue represents insulin, red is glucagon, and green is somatostatin.
Pancreatic progenitor cells made from human embryonic stem cells in vitro are loaded into encapsulation device before transplantation. Cells mature into the different pancreatic endocrine cells, including importantly, insulin-expressing beta cells. These cells produce insulin in response to glucose, effectively replacing the insulin that is lost in people with type 1 diabetes. ViaCyte has several CIRM grants to develop a stem cell-based therapy for type 1 diabetes based on this work.
Image taken by Kuniko Kadoya, PhD at Viacyte, Inc.